Aura Biosciences, Inc. (NASDAQ: AURA) is a Healthcare company (Biotechnology) with a market capitalization of $744M. The Maz Rating grades it against the other companies in its sector.
Aura Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.15, Aura Biosciences, Inc. trades at 2.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -64.7%, return on invested capital of -47.8% and a free cash flow yield of -14.7%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 14.21. Over the past 52 weeks the share price ranged from $4.73 to $9.54, with a beta of 0.41.
Aura Biosciences, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Aura Biosciences, Inc. (AURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 45.0% / 30% · Interest income / Revenue 301700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 45.0% / 33% · Receivables / Mkt Cap (36m) 0.28% / 49% · Interest income / Revenue 301700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 45.0% / 33.33% · Receivables / Mkt Cap (24m) 0.28% / 33.33% · Interest income / Revenue 301700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.85% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.1% / 33.33% · Receivables / Avg Assets (4Q) 0.19% / 33.33% · Interest income / Revenue 301700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.4% / 33.33% · (Cash+Recv) / Total Assets 93.0% / 33.33% · Interest income / Revenue 301700000.0% / 5% | Fail |
No. As of September 2026, Aura Biosciences, Inc. (AURA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Aura Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 301700000.0% of each dividend: Aura Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.